The role of β‐blockers in dermatological treatment: a review

Chen, L.; Tsai, Tsen‐Fang

doi:10.1111/jdv.14566

Cited by 23 publications

(21 citation statements)

References 83 publications

(131 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral b-blockers might be useful to treat persistent erythema and flushing because they antagonize the effects of sympathetic nerve stimulation and circulating catecholamines at b-adrenoceptors [42][43][44]. In a systematic review including nine studies, Logger and colleagues concluded that oral nonselective b-blockers, especially carvedilol and propranolol, may be an effective treatment option for rosacea-associated facial flushing and erythema [43].…”

Section: Oral Therapiesmentioning

confidence: 99%

Rosacea Treatment: Review and Update

Zhang

Tang

Wang

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Rosacea is a chronic and inflammatory skin disease characterized by flushing, nontransient erythema, papules/pustules, telangiectasia, and phymatous changes. Secondary manifestations, such as itching, burning, or stinging, are often observed in patients with rosacea. In 2017, a phenotype-based approach for diagnosis and classification was recommended. With the update of the diagnosis and classification of rosacea, treatment options for patients with rosacea have attracted the attention of dermatologists. Here, we summarize the latest advances in rosacea treatment, including skin care and cosmetic treatments, topical therapies, oral therapies, laser- and light-based therapies, injection therapies, treatments for specific types of rosacea, treatments for systemic comorbidities, and combination therapies. The impact of the phenotype-based approach on rosacea treatment and future directions are also discussed.

show abstract

Section: Oral Therapiesmentioning

confidence: 99%

Rosacea Treatment: Review and Update

Zhang

Tang

Wang

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…β3-AR, that are more sensitive to the action of noradrenaline, are mainly expressed in brown adipose tissue, where they activate lipolysis together with β1-AR, and in skeletal muscle, where they contribute to thermogenesis (Balligand 2013). Beta2-AR are also expressed on skin, where they can be found in secretory coil of apocrine glands, keratinocytes, fibroblasts and melanocytes (Chen and Tsai 2017).…”

Section: Beta-adrenergic System and Pharmacology Of β-Blockersmentioning

confidence: 99%

The Role of β-Blockers in Melanoma

Giorgi

Geppetti

Lupi

et al. 2019

J Neuroimmune Pharmacol

View full text Add to dashboard Cite

Melanoma is one of the most aggressive and less chemotherapy-responsive human cancers, representing a major public health issue worldwide. The early diagnosis still represents the best approach in order to reduce mortality, especially in advanced stages. Preclinical evidence, collected through several in vitro and in vivo models, has been accumulating about the pathophysiological involvement of β-adrenoceptors in melanoma progression. This involvement has been paralleled by the evidence that drugs blocking β-adrenoceptors (β-blockers) may have a relevant role in the treatment of melanoma and in the prevention of its progression. β-blockers are a class of drugs extensively used in clinical practice, not limited to cardiovascular therapeutics. Evidence collected through retrospective and prospective observational studies suggests that treatment with β-blockers, mainly propranolol, is able to delay melanoma progression. Although conclusive evidence is still lacking, current knowledge proposes βblockers as an opportunity for antitumor treatment in melanoma. Clinical trials are needed in order to prove their claimed efficacy.

show abstract

“…They share the ability to produce potentially severe adverse effects, especially in predisposed areas or areas of locus minoris resistentiae in the skin. Consequent upon review, potential alternatives have been proposed (4–10).…”

Section: Introductionmentioning

confidence: 99%

Immunologic adverse reactions of β-blockers and the skin (Review)

Tatu¹,

Elisei²,

Chioncel

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

β-Blockers are a widely utilised class of medication. They have been in use for a variety of systemic disorders including hypertension, heart failure and intention tremors. Their use in dermatology has garnered growing interest with the discovery of their therapeutic effects in the treatment of haemangiomas, their potential positive effects in wound healing, Kaposi sarcoma, melanoma and pyogenic granuloma, and, more recently, pemphigus. Since β-blockers are deployed in a variety of disorders, which have cutaneous co-morbidities such as psoriasis, their pertinence to dermatologists cannot be overstated. Likewise, β-blockers, like any other drug category, carry risks of side effects, some of which are dermatologic. These include triggering and exacerbation of psoriasis, psoriatic and rheumatoid arthritis, anaphylaxis, contact dermatitis, occupational contact dermatitis, Raynaud's disease, alopecia, lichen planus-like drug eruption, hyperhydrosis and vitiligo. While recent articles have focussed on the positive uses of β-blockers, it may also be wise to call our attention to the potential dermatologic adverse effects that may follow β-blocker use, as well as possible therapeutic approaches to these. This short review will focus on those dermatoses resulting from β-blocker use, which have an immunologic basis.

show abstract

The role of β‐blockers in dermatological treatment: a review

Cited by 23 publications

References 83 publications

Rosacea Treatment: Review and Update

Rosacea Treatment: Review and Update

The Role of β-Blockers in Melanoma

Immunologic adverse reactions of β-blockers and the skin (Review)

Contact Info

Product

Resources

About